Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr402His polymorphism

Molecular Vision

Volumn 18, Issue , 2012, Pages 2288-2299

  Silva, Aldacilene Souza ^a   Teixeira, Anderson Gustavo ^b   Bavia, Lorena ^a   Lin, Fabio ^a   Velletri, Roberta ^b   Belfort, Rubens ^b   Isaac, Lourdes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; HISTIDINE; TYROSINE;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IMMUNODIFFUSION; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RETINA MACULA AGE RELATED DEGENERATION; SEX DIFFERENCE;

EID: 84865832172     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41:355-67. [PMID: 15163532]
2. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25:1265-75. [PMID: 17989689]
3. Mandal MN, Ayyagari R. Complement factor H: spatial and temporal expression and localization in the eye. Invest Ophthalmol Vis Sci 2006; 47:4091-7. [PMID: 16936129]
4. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31:424-8. [PMID: 12091909]
5. Józsi M, Zipfel PF. Factor H family and human diseases. Trends Immunol 2008; 29:380-7. [PMID: 18602340]
6. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-66. [PMID: 11287977]
7. Sharma AK, Pangburn MK. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci USA 1996; 93:10996-11001. [PMID: 8855297]
8. McGeer PL, Mcgeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10:S3-7. [PMID: 15109580]
9. Brück W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003; 24:S265-7. [PMID: 14652785]
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95. [PMID: 15843671]
11. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134:411-31. [PMID: 12208254]
12. Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA 2005; 102:7053-4. [PMID: 15886281]
13. Donoso LA, Vrabec T, Kuivaniemi H. The role of complement Factor H in age-related macular degeneration: a review. Surv Ophthalmol 2010; 55:227-46. [PMID: 20385334]
14. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291:704-10. [PMID: 14871913]
15. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, Mccarty C, De Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-72. [PMID: 15078675]
16. Niederkorn JY. A renewed appreciation for ocular immune privilege. Arch Soc Esp Oftalmol 2005; 80:437-8. [PMID: 16136394]
17. Cummings M, Cunha-Vaz J. Treatment of neovascular agerelated macular degeneration in patients with diabetes. Clin Ophthalmol. 2008; 2:369-375. [PMID: 19668728]
18. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG. Drusen. proteome analysis: an. approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99:14682-7. [PMID: 12391305]
19. Skerka C, Lauer N, Hatmann A, Heinan S, Schlötzerschrehardt U, Weinberger AWA, Keilhauer C, Suehnel J, Weber BHF, Zipfel PF. Mutation in factor H (Y402H) associated with age-related macular degeneration (AMD) results in reduced binding activities. Mol Immunol 2007; 44:241.
20. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs M, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102:7227-32. [PMID: 15870199]
21. Klein RJ, Zeiss C, Chew EY, Tsai JT, Sackler RS, Haynes C, Henning AK, Sangiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement Factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-9. [PMID: 15761122]
22. Edwards AO, Ritter IR, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement Factor H polymorphism and agerelated macular degeneration. Science 2005; 308:421-4. [PMID: 15761121]
23. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P, Cano M, Brandstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011; 478:76-81. [PMID: 21979047]
24. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108:235-48. [PMID: 21252151]
25. Suzuki M, Kamei M, Itabe H, Yoneda K, Bando H, Kume N, Tano Y. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis 2007; 13:772-8. [PMID: 17563727]
26. Teixeira AG, Silva AS, Lin FLH, Velletri R, Bavia L, Belfort R Jr, Isaac L. Association of complement factor H Y402H polymorphism and age-related macular degeneration in Brazilian patients. Acta Ophthalmol 2010; 88:e165-9. [PMID: 20626361]
27. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodifusion. Immunochem. 1965; 2:235-54.
28. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007; 16 Spec No. 2:R174-82. [PMID: 17911160]
29. Sivakumaran TA, Igo RP Jr, Kidd JM, Itsara A, Kopplin LJ, Chen W, Hagstrom SA, Peachey NS, Francis PJ, Klein ML, Chew EY, Ramprasad VL, Tay WT, Mitchell P, Seielstad M, Stambolian DE, Edwards AO, Lee KE, Leontiev DV, Jun G, Wang Y, Tian L, Qiu F, Henning AK, LaFramboise T, Sen P, Aarthi M, George R, Raman R, Das MK, Vijaya L, Kumaramanickavel G, Wong TY, Swaroop A, Abecasis GR, Klein R, Klein BE, Nickerson DA, Eichler EE, Iyengar SK. A 32 kb critical region excluding Y402H in CFH mediates risk for age-related macular degeneration. PLoS ONE 2011; 6:e25598. [PMID: 22022419]
30. Conley YP, Thalamuthu A, Jakobsdottir J, Weeks DE, Mah T, Ferrel R, Gorin MB. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum Mol Genet 2005; 14:1991-2002. [PMID: 15930014]
31. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-21. [PMID: 15761120]
32. Magnusson KP, Duan S, Sigurdsson H, Petursson H, Yang Z, Zhao Y, Bernstein PS, Ge J, Johnsson F, Stefansson E, Helgadottir G, Zabriskie NA, Johnsson T, Björnsson A, Thorlacius T, Jonsson PV, Thorleifsson G, Kon GA, Stefansson H, Zhang K, Stefansson K, Gulcher CFH Jr. Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3:e5. [PMID: 16300415]
33. Sepp T, Khan JC, Thurlby DA, Shahid H, Clayton DG, Moore AT, Bird AC, Yates JR. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and non smokers. Invest Ophthalmol Vis Sci 2006; 47:536-40. [PMID: 16431947]
34. Scholl HP, Weber BH, Nöthen MM, Wienker T, Holz FG. Y402H polymorphism in complement factor H and agerelated macula degeneration (AMD). Ophthalmologe 2005; 102:1029-35. [PMID: 16170519]
35. Souied EH, Leveziel N, Richard F, Dragon-Durey MA, Coscas G, Soubrane G, Benlian P, Fremeaux-Bacchi V. Y402H Complement factor H polymorphism associated with exsudative age-related degeneration in the French population. Mol Vis 2005; 11:1135-40. [PMID: 16379025]
36. Simonelli F, Frisso G, Testa F, Di Fiore R, Vitale DF, Manitto MP, Brancato R, Rinaldi E, Sacchetti L. Polymorphism 402Y>H in the complement factor H protein is a risk factor for age related macular degeneration in an Italian population. Br J Ophthalmol 2006; 90:1142-5. [PMID: 16774956]
37. Tedeschi-Blok N, Buckley J, Varma R, Triche TJ, Hinton DR. Population-based study of early age-related macular degeneration role of the complement factor H T402H polymorphism in bilateral but not unilateral disease. Ophtalmol. 2007; 114:99-103.
38. Kaur I, Hussain A, Hussain N, Das T, Pathangay A, Mathai A, Hussain A, Nutheti R, Nirmalan PK, Chakrabarti S. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. Invest Ophthalmol Vis Sci 2006; 47:3729-35. [PMID: 16936080]
39. Lau LI, Chen SJ, Cheng CY, Yen MY, Lee FL, Lin MW, Hsu WM, Wei YH. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci 2006; 47:3242-6. [PMID: 16877387]
40. Kim NR, Kang JH, Kwon OW, Lee SJ, Oh JH, Chin HS. Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans. Invest Ophthalmol Vis Sci 2008; 49:2071-6. [PMID: 18223247]
41. Chowers I, Chowers I, Cohen Y, Goldenberg-Cohen N, Vicunakojchen J, Lichtinger A, Weinstein O, Pollack A, Axer-Siegel R, Hemo I, Averbukh E, Banin E, Meir T, Lederman M. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol Vis 2008; 14:1829-34. [PMID: 18852870]
42. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001; 73:887-896. [PMID: 11846519]
43. Klein R, Klein BE, Tomany SC, Wong TY. The relation of retinal microvascular characteristics to age-related eye disease: the Beaver Dam eye study. Am J Ophthalmol 2004; 137:435-44. [PMID: 15013865]
44. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV. Do gene-environment interactions influence fasting plasma lipids? A study of twins. Eur J Clin Invest 2004; 34:590-8. [PMID: 15379757]
45. Wener MH, Daum PR, Mcquillan GM. The influence of age, sex, and race on the upper reference limit of serum Creactive protein concentration. J Rheumatol 2000; 27:2351-9. [PMID: 11036829]
46. Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, Rodríguez de Córdoba S. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004; 56:77-82. [PMID: 15118848]
47. Scholl HP, Charbel-Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BH, Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS ONE 2008; 3:e2593. [PMID: 18596911]
48. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith R, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38:458-62. [PMID: 16518403]
49. Spencer KL, Hauser MA, Olson LM, Schmidt S, Scott WK, Gallins P, Agarwal A, Postel EA, Pericak-Vance MA, Haines JL. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet 2007; 16:1986-92. [PMID: 17576744]
50. Chen M, Muckersie E, Robertson M, Forrester JV, Xu H. Upregulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina. Exp Eye Res 2008; 87:543-50. [PMID: 18926817]
51. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. Plasma complement and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009; 50:5818-27. [PMID: 19661236]
52. Stanton CM, Yates JRW, den Hollander AI, Seddon JM, Swaroop A, Stambolian D, Fauser S, Hoyng C, Yu Y, Atsuhiro K, Branham K, Othman M, Chen W, Kortvely E, Chalmers K, Hayward C, Moore AT, Dhillon B, Ueffing M, Wright AF. Complement Factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52:8828-34. [PMID: 22003108]
53. Williams LW, Burks AW, Steele RW. Complement: function and clinical relevance. Ann Allergy 1988; 60:293-300. [PMID: 3282455]
54. Rohrer B, Guo Y, Kunchithapautham K, Gilkeson GS. Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci 2007; 48:5282-9. [PMID: 17962484]
55. Kluin-Nelemans HC, Van Velzen-Blad H, Van Helden HP, Daha MR. Function al deficiency of complement factor D in a monozygous twin. Clin Exp Immunol 1984; 58:724-30. [PMID: 6568950]
56. Hiemstra PS, Langeler E, Compier B, Keepers Y, Leijh PC, Van Den Barselaar MT, Overbosch D, Daha MR. Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest 1989; 84:1957-61. [PMID: 2687330]
57. Biesma DH, Hannema AJ, Van Velzen-Blad H, Mulder L, Van Zwieten R, Kluijt I, Roos DJ. A family with complement factor D deficiency. J Clin Invest 2001; 108:233-40. [PMID: 11457876]
58. Zeng J, Chen Y, Tong Z, Zhou X, Zhao C, Wang K, Hughes G, Kasuga D, Bedell M, Lee C, Ferreyra H, Kozak I, Haw W, Guan J, Shaw R, Stevenson W, Weishaar PD, Nelson MH, Tang L, Zhang K. Lack of association of CFD polymorphisms with advanced age-related macular degeneration. Mol Vis 2010; 16:2273-8. [PMID: 21139680]
59. Ishida O, Oku H, Ikeda T, Nishimura M, Kawagoe K, Nakamura K. Is Chlamydia pneumoniae infection a risk factor for age related macular degeneration? Br J Ophthalmol 2003; 87:523-4. [PMID: 12714382]
60. Robman L, Mahdi OS, Wang JJ, Burlutsky G, Mitchell P, Byrne G, Guymer R, Taylor H. Exposure to Chlamydia pneumoniae infection and age-related macular degeneration: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2007; 48:4007-11. [PMID: 17724180]
61. Shen D, Tuo J, Patel M, Herzlich AA, Ding X, Chew EY, Chan CC. Chlamydia pneumoniae infection, complement factor H variants and age-related macular degeneration. Br J Ophthalmol 2009; 93:405-8. [PMID: 18996904]
62. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet 2009; 17:100-4. [PMID: 18685559]
63. Schlaf G, Demberg T, Beisel N, Schieferdecker HL, Götze O. Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 2001; 38:231-9. [PMID: 11532284]
64. Spencer KL, Olson LM, Anderson BM, Schnetz-Boutaud N, Scott WK, Gallins P, Agarwal A, Postel EA, Pericak-Vance MA, Haines JL. C3 R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet 2008; 17:1821-4. [PMID: 18325906]
65. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary LJ, Redmond E, Bird AC, Moore AT. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357:553-61. [PMID: 17634448]
66. Kijlstra A, La Heij E, Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 2005; 13:3-11. [PMID: 15804763]
67. Wang J, Ohno-Matsui K, Yoshida T, Kojima A, Shimada N, Nakahama KI, Safranova O, Iwata N, Saido TC, Mochizuki M, Morita I. Altered function of factor I caused by amyloid β: implication for pathogenesis of age-related macular degeneration from drusen. J Immunol 2008; 181:712-20. [PMID: 18566438]
68. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3:1618-27. [PMID: 16102027]
69. Hawkins MA. Markers of increased cardiovascular risk: are we measuring the most appropriate parameters? Obes Res 2004; 12:107S-114S. [PMID: 15601958]
70. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80. [PMID: 7512342]
71. Vaith P, Prasauskas V, Potempa LA, Peter HH. Complement activation by C-reactive protein on the HEp-2 cell substrate. Int Arch Allergy Immunol 1996; 111:107-17. [PMID: 8859218]
72. Sjöwall C, Wetterö J, Bengtsson T, Askendal A, Almroth G, Skogh T, Tengvall P. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluidphase CRP-C1q interaction. Biochem Biophys Res Commun 2007; 352:251-8. [PMID: 17113035]
73. Jarvis JN, Xu C, Wang W, Petty HR, Gonzalez M, Morssy N, Waxman F, Quintero Del Rio A. Immune complex size and complement regulate cytokine production by peripheral blood mononuclear cells. Clin Immunol 1999; 93:274-82. [PMID: 10600339]
74. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42:23-30. [PMID: 10408362]
75. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353-64. [PMID: 11067883]
76. Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, Mold C, Gordon DL. A common site within factor H SCR 7 responsible for binding heparin, Creactive protein and streptococcal M protein. Eur J Immunol 2003; 33:962-9. [PMID: 12672062]
77. Agrawal A. CRP after 2004. Mol Immunol 2005; 42:927-30. [PMID: 15829284]
78. Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006; 26:935-41. [PMID: 16456095]
79. Sjöberg AP, Trouw LA, Clark SJ, Sjölander J, Heinegård D, Sim RB, Day AJ, Blom AM. The factor H variant associated with age-related macular degeneration (H384) and the non-disease associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem 2007; 282:10894-900. [PMID: 17293598]
80. Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, De Jong PT. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 2007; 125:1396-401. [PMID: 17923549]
81. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the agerelated macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci USA 2006; 103:17456-61. [PMID: 17079491]
82. Laine M, Jarva H, Seitson ENS, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Järvelä I, Jokiranta TS, Hageman GS, Immonen I, Meri S. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007; 178:3831-6. [PMID: 17339482]
83. McGwin G Jr, Xie A, Owsley C. The use of cholesterollowering medications and age-related macular degeneration. Ophthalmology 2005; 112:488-94. [PMID: 15745779]
84. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and etiological aspects of macular degeneration. Prog Retin Eye Res 2001; 20:385-414. [PMID: 11286898]
85. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20:705-32. [PMID: 11587915]